# A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

> **NCT07633756** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 15 (estimated)

## Conditions studied

- Phase 1b
- Open Label
- REC-617
- RB1-Negative
- Leiomyosarcoma

## Interventions

- **DRUG:** REC617

## Key facts

- **NCT ID:** NCT07633756
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-19
- **Primary completion:** 2029-12-26
- **Final completion:** 2031-12-26
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07633756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07633756, "A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07633756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*